

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C11C 3/10, A61K 31/23, A23L 1/30</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 98/56883</b> <b>(43) International Publication Date:</b> 17 December 1998 (17.12.98)
<b>(21) International Application Number:</b> PCT/EP98/03466 <b>(22) International Filing Date:</b> 9 June 1998 (09.06.98)  <b>(30) Priority Data:</b> MI97A001369 11 June 1997 (11.06.97) IT  <b>(71)(72) Applicant and Inventor:</b> GALLIANI, Guido [IT/IT]; Via Santa Liberata, 62, I-20033 Desio (IT).  <b>(72) Inventor; and</b> <b>(75) Inventor/Applicant (for US only):</b> TACCONI, Maria, Teresa [IT/IT]; Via Losanna, 27, I-20154 Milano (IT).  <b>(74) Agent:</b> MINOJA, Fabrizio; Bianchetti Bracco Minoja S.r.l., Via Rossini, 8, I-20122 Milano (IT).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> WAX ESTERS ENRICHED IN $\omega$ -3 UNSATURATED FATTY ACIDS, THEIR PREPARATION AND THEIR USE		
<b>(57) Abstract</b>  This invention refers to wax esters enriched in $\omega$ -3 unsaturated fatty acids, to the procedure to obtain them, to their peculiar biochemical behaviour which enables them to be used as drug and food additives, and to formulations which contain them for both pharmaceutical and dietetic-alimentary purposes.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

WAX ESTERS ENRICHED IN  $\omega$ -3 UNSATURATED FATTY ACIDS.  
THEIR PREPARATION AND THEIR USE

This invention refers to wax esters enriched in  $\omega$ -3 unsaturated fatty acids, to the procedure to obtain them, to their peculiar biochemical behaviour which enables them to be used as drug and food additives, and to formulations which contain them for both pharmaceutical and dietetic-alimentary purposes.

The name "wax" usually means a wide class of lipids, which are characterized more according to their physical feature than according to their chemical structure. Generally, a material is classified as a wax when it looks like honeycomb material.

On the contrary, from a strictly chemical point of view, waxes are particular carboxylic esters (wax esters). Namely, they are esters of long chain aliphatic acids (fatty acids) with long chain aliphatic alcohols. Both acids and alcohols can be either saturated or unsaturated. A full description of nature and characteristics of wax esters can be found in a review by P.E.Kolattukudy, "Chemistry and Biochemistry of Natural Waxes", Elsevier (1976), Amsterdam.

The starting material to be used in the preparation of products herein described is a mixture of esters enriched in  $\omega$ -3 unsaturated fatty acids. This mixture is usually obtained by current industrial procedures from natural sources such as fish oil, containing a relatively high amount of polyunsaturated  $\omega$ -3 fatty acids, such as EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid). In a common procedure, fish oil

2

triglycerides are split by treatment with low boiling alcohols in the presence of a catalyst. After removing glycerol, esters thus obtained are further enriched in  $\omega$ -3 unsaturated fatty acids by some techniques, such as distillation and urea fractionation.

Methyl and ethyl esters, enriched in EPA and DHA, along with natural or synthetical triglycerides, and free fatty acids, also enriched in EPA and DHA, have been the forms so far available for material enriched in  $\omega$ -3 polyunsaturated acid, to be used as both pharmaceuticals and food integrators.

These forms have severe drawbacks, mainly due to their tendency to oxidation. These products go easily rancid when exposed to air. Oxidation by-products, even at a low content, render the main material stenching, irritant and disgusting, so that this cannot be easily handled and utilized.

From a technological standpoint, moreover, polyunsaturated fatty acids, their glycerides, and their esters with low boiling alcohols are thick oily liquids, so they are hard to formulate. The best solution so far used is to formulate them in soft jelly capsules, but also this expedient is not able to cancel inconveniences such as burping after ingestion.

Surprisingly, we have found that wax esters herein described can easily override these difficulties. Products herein described are easily handled since they are solid and less prone to oxidation. Nevertheless, the biological properties remain the same as in the case of all those oily derivatives mentioned before. Surprisingly, as a matter of fact, we have discovered

that wax esters enriched in  $\omega$ -3 polyunsaturated fatty acids are much more readily absorbed and metabolized than wax esters naturally encountered, characterized by a low contents in  $\omega$ -3 fatty acids.


5 Products herein described are solid waxy materials, so that oxidation is limited to the only surface layer. Therefore, they can be formulated in several ways, preserving their biological and organoleptic properties.

Beneficial effects of  $\omega$ -3 fatty acids, particularly of EPA and DHA, are well known for pathologies affecting the cardio-circulatory system (thrombosis, atherosclerosis, platelet hyperaggregation, hyperlipidemia, hypercholesterolemia), as well as for pathologies affecting the immune system, in inflammatory states, and in tumors. Moreover, the effects of lack of dietary DHA have been described (Tacconi M.T., Lligona L., Salmona M., Pitsikas M., and Algeri S., Neurobiol. of Aging, 12:55-59, 1990).

15 This invention concerns therefore also the use of wax esters herein described in the preparation of drugs which can conveniently be used in the aforementioned pathologies, as well as in the preparation of dietetic and alimentary formulations.

Wax esters herein described are prepared from a mixture of esters of free fatty acids enriched in polyunsaturated fatty acids, where the alcohol moiety is usually methyl or ethyl alcohol, or, more generally, a low boiling alcohol. This mixture is reacted with one or more alcohols via a transesterification reaction, provided that these alcohols are the same ones found in natural wax esters, according to the following scheme:

4



where R: residue of an  $\omega$ -3 unsaturated fatty acid,  
R'' : methyl, ethyl, or a low boiling alcohol residue,  
R' : residue of an alcohol contained in natural wax  
5 esters.

For R, EPA and DHA residues are preferred. For R'',  
methyl and ethyl are preferred. Finally, for R',  
residues of saturated alcohols are preferred, with a  
number of carbon atoms ranging from 12 and 40. Another  
10 preferred alcohol is oleyl alcohol.

The aforementioned scheme is not restrictive, since  
a mixture of esters RCOOR'' can be simultaneously reacted  
with a mixture of alcohols R'OH, provided that, as  
stated before, the mixture represented by the formula  
15 RCOOR'' is enriched in  $\omega$ -3 unsaturated fatty acids,  
i.e., as an example, when RCOOR'' represents the esters  
of EPA and DHA, these are contained in this mixture in  
percentage higher than 18% and 12% respectively,  
corresponding to the percentages of these two acids  
20 usually found in natural products.

Optimally, the reaction is performed starting from  
nearly stoichiometric amount of the reactants, and it is  
catalyzed by bases, according to procedures usually  
adopted for transesterifications. The product is  
25 obtained with the highest yield when low boiling alcohol  
R''OH is removed as a reaction product by distillation  
under reduced pressure.

After completion, the reaction mixture is treated  
with hot water containing small amounts of an acid,  
30 preferably citric acid, in order to quench and remove  
the catalyst, along with small traces of soap formed

during the reaction. Further addition of hot water separates the wax ester as a melted liquid phase, which is allowed to separate and to solidify.

Wax esters described by this invention can be  
5 recrystallized in small white needle-shaped crystals. They can also be purified without any crystallization, simply by repeating the washing of the oily phase with some more water and citric acid. The product thus obtained can undergo a final treatment of deodorization,  
10 in order to remove by-products from oxidation, according to procedures usually used in alimentary oil technology.

According to the procedure thus described, the content of  $\omega$ -3 unsaturated fatty acids in the final wax ester is the same as in the starting mixture of esters,  
15 as shown by the analysis of the acidic moiety obtained by hydrolysis of wax esters.

Transesterification reaction is the best suited procedure in order to obtain wax esters highly enriched in polyunsaturated fatty acids, but also other reactions  
20 can give the same products, starting both from esters enriched in polyunsaturated acids and from free fatty acids obtained by hydrolizing these esters. Some of these reactions can be mentioned, such as direct esterification of free fatty acids with alcohols,  
25 treatment of alcohols with reactive derivatives of acids, such as anhydrides, chlorides, isopropenyl esters, and so on, interesterification of either methyl or ethyl esters of fatty acids with either acetic or propionic esters of long chain alcohols.

30 Wax esters herein described are more stable toward air oxidation than the starting esters, as shown by the

parallel determination of peroxide number, made at increasing times, of a sample of ethyl ester enriched in EPA and DHA and of the corresponding wax ester, when both samples were allowed to stand in an open vessel.

5 After one week of exposure to air, peroxide number was increased from five to seven times more in the case of ethyl esters than in the case of wax esters; values were corrected on the basis of the actual weight of polyunsaturated fatty acid in the molecular formula of

10 ethyl esters and of wax esters.

Similar results were obtained by monitoring the formation of formaldehyde as an oxidative by-product. Tests were performed according to Wilbur et al., Arch.Biochem.Biophys, 24:305,1949 as modified by

15 Kikugawa et al. Anal.Biochem. 202:249, 1992 and they are reported in Table 1.

Table 1

Peroxidability of wax esters (200 mg) *in vitro* in comparison with same amounts of fish oil.

20

Time after incubation	Wax esters	Fish oil absorbance (thiobarbituric acid reaction substances, TBARS, malondialdehyde units)
-----------------------	------------	--

25

day 1	0.160	1.295
day 2	0.323	1.996
day 3	2.362	5.081

30

As to absorption and biotransformation of wax



esters described by this invention, it has been found that these compounds are well absorbed and that they are actually metabolized, contrary to what described in the case of natural wax esters, which are not enriched in polyunsaturated fatty acids.

Digestibility of the products described by this invention was tested in *in vitro* experiments. After digestion with pancreas lipase, the hydrolysis of wax esters was monitored on the basis of formation of both the alcoholic and the acidic moieties. As a reference, jojoba oil was used, which is a natural oil containing an acid moiety where monounsaturated fatty acid are in the majority, and an alcoholic moiety containing prevailing saturated chains. Thin layer chromatographic analysis clearly showed that wax esters enriched in  $\omega$ -3 unsaturated fatty acids were nearly completely hydrolyzed into their constituents already after 5 hours, whereas jojoba oil was nearly unreacted.

*In vivo* tests were performed on rats treated with a single dose of 5g/kg of wax esters (acute treatment). Animals were killed 6 and 16 hours after the treatment. Results are reported in Tables 2 and 3.

Table 2 shows that plasma triglycerides are raised, in comparison with untreated animals, at both times after the treatment. Table 3 clearly shows that the plasma of treated animals was noticeably enriched in EPA and DHA 6 hours after the treatment, in comparison with untreated animals. No effect is visible after 16 hours from the treatment, probably because the rapid metabolism of lipids.

A protocol was also applied in order to study the

effects of a chronic treatment. With a dose of 0.3 g/kg repeated for 15 days, no change in the weight of animals was noticed. Food consumption slightly decreased, whereas intestinal transit was not altered, as shown by Table 4. These results are in sharp contrast with results described in the case of natural waxes, where polyunsaturated acids are not major constituents of the acidic moiety (see the review quoted above, by P.E. Kolattukudy). *In vivo* tests are in agreement with *in vitro* results and all of them reinforce the evidence that enrichment of wax esters in  $\omega$ -3 unsaturated acids results in complete absorption and digestibility.

Table 2

Effect of an acute treatment with wax esters (5 g/kg, oral) on plasma lipids of rats

	Time after treatment (h)	Cholesterol mg/dl $\pm$ SD	Triglycerides
20	Control	-	64.7 $\pm$ 1.5
	Wax esters	6	82.2 $\pm$ 5.5
	Wax esters	16	60.0 $\pm$ 10.7
			99.2 $\pm$ 6.9
			68.9 $\pm$ 2.2
			129.0 $\pm$ 5.3

Table 3

Effect of an acute treatment with wax esters (5 g/kg, oral) on the rat plasma content in fatty acids.

5	Fatty acid	Control	Main plasma fatty acids (moles %)	
			6 hours after treatment	16 hours after treatment
	12:0	0.2	0.2	0.2
10	14:0	0.5	0.3	0.5
	15:0	0.3	0.2	0.5
	16:0	21.0	13.6	20.4
	18:0	13.7	12.6	8.8
	18:1	14.9	8.1	14.2
15	18:2 $\omega$ 3	25.4	18.3	32.5
	18:3 $\omega$ 3	1.7	1.1	2.1
	20:2	0.1	1.0	0.8
	20:3 $\omega$ 6	0.5	0.5	0.8
	20:4 $\omega$ 6	9.7	13.4	6.3
20	20:5 $\omega$ 3 (EPA)	2.3	6.1	2.4
	22:2	1.5	5.9	1.1
	22:4	0.4	4.6	1.8
	22:5 $\omega$ 3	1.7	4.5	1.4
	22:6 $\omega$ 3 (DHA)	4.7	7.0	2.6
25	total $\omega$ 6	37.0	42.2	41.7
	total $\omega$ 3	10.4	18.7	8.5

Table 4

Effect of a subchronic treatment with wax ester (0.3 g/kg each day, for 15 days) on body weight, food consumption, and intestinal transit of rats.

		Initial body	Final body	Food consumption	
		weight	weight	Intestinal	
		(g $\pm$ SD)		g/rat/day	transit %
10	Control	174 $\pm$ 6.5	261 $\pm$ 4.0	31.0	48.0
	Wax esters	173 $\pm$ 4.0	261 $\pm$ 5.6	27.3	52.6

As a conclusion, studies both *in vivo* and *in vitro* show the efficacy of the products described by this invention as a source of  $\omega$ -3 unsaturated fatty acids, as good as other products presently on the market. In addition, contrary with what met in the case of current products, these new products offer many advantages from a technological and formulative point of view.

Some formulative aspects, which concern only the products herein described, deserve some mention. For instance, wax esters can be sprayed in melted form and injected into cold water, where droplets of the product solidify in the form of small spheres with a prefixed radium. The procedure can be performed with water treated with salt and natural fragrances, in order to obtain synthetic caviar.

As an alternative, wax esters can be absorbed onto a solid matrix (flour, bran, granules, and so on) in order to obtain foods enriched in  $\omega$ -3 unsaturated fatty acids.

In the pharmaceutical field, products described by this invention can be formulated using conventional excipients and techniques, such as described in "Remington's Pharmaceutical Sciences Handbook" Mack  
5 Publishing Company, New York, USA.

Therefore, this invention concerns also dietetic and pharmaceutical formulations containing wax esters enriched in  $\omega$ -3 unsaturated fatty acids which can be obtained according to the procedures herein described.

10 The following examples, reporting the preparation of some wax esters enriched in  $\omega$ -3 unsaturated fatty acids, explain the invention in better details.

Example 1. 25 gr of an enriched fish oil ester (saponification value = 170 mg KOH/gr, average molecular  
15 weight 330, EPA 33%, DHA 22% as from gaschromatographic area percent analysis) was mixed with 25 gr of behenyl alcohol (molecular weight 326). The mixture was treated with 0.3 gr of sodium methoxide and the flask was connected to a vacuum pump (40 mbar). Temperature was  
20 raised up to 120°C. The stirred mixture darkened, as ethanol started boiling at ca. 80°C. A temperature of 120°C was maintained for half an hour. During this time, ethanol evolution almost ceased. The mixture was then cooled at 40°C, then the vacuum was removed by filling  
25 the flask with nitrogen. The liquid mixture was poured into a 1% aqueous solution of citric acid (200 ml) stirred under nitrogen at room temperature. Stirring was continued for five minutes at room temperature, then the mixture, still stirred, was cooled down to 5°C, whereby  
30 crystallization occurred. The solid material was filtered under vacuum, washed with water on the filter,

12

and recrystallized from 400 ml of acetone. After cooling the mixture at  $-10^{\circ}\text{C}$  for one hour, the whitish crystalline product was filtered under vacuum and dried under reduced pressure overnight at room temperature.

5 Yield: 42.5 gr (89%). The product gives a clean spot in TLC (silica gel plates, eluting system; n-hexane-ethyl ether 9:1,  $R_f = 0.87$ , whereas  $R_f$  of the starting ethyl ester = 0.75,  $R_f$  of behenyl alcohol = 0.11). The melting point of the wax was  $47^{\circ}\text{C}$ .

10 Example 2. The same ethyl ester of example 1 (33 gr) was reacted with 27 gr of stearyl alcohol (molecular weight 270). Reaction conditions were the same as for example 1. Yield: 43.5 gr (67.5%), after crystallization from 200 ml of acetone. A clear spot in TLC was detected  
15 (silica gel, m-hexane-ethyl ether 49:1;  $R_f = 0.23$ ). By superimposing this product with product of example 1, no separation can be observed. Melting point:  $39^{\circ}\text{C}$ .

Example 3. 25 gr of an ethyl ester enriched in EPA (74% EPA), with no DHA, (saponification value: 170, average  
20 molecular weight 330) were reacted with 25 gr of behenyl alcohol. Reaction conditions were the same as for example 1. The product obtained from water was not completely soluble even in large amounts of hot acetone, so it was filtered as it was a melted phase through a  
25 paper filter and dried under reduced pressure. Yield: 39.4 gr (82.7%): Melting point:  $40^{\circ}\text{C}$ .

Example 4. 25 gr of ethyl ester (the same as in Example 1) were reacted with 16.2 gr of 1-tetradecanol (molecular weight 214). Reaction conditions were the  
30 same as for example 1. After pouring the mixture into acidic water, the oily phase was washed twice at  $45^{\circ}\text{C}$

13

with 100 ml of water. After separation, the oily phase was then dried under reduced pressure. Yield: 35 gr (90%). Melting point: 23°C. Thin layer chromatography showed a neat spot, with the same  $R_f$  of the products of examples 1, 2, and 3.

Example 5. 33 gr of the same ethyl ester of example 1 (33% EPA, 22% DHA) were reacted by the same procedure of Example 1 with 24 gr of 1 hexadecanol (cetyl alcohol). The solid filtered from water at 3°C was stirred in 50 ml of cold acetone (at -10°C) for half an hour, then it was filtered under vacuum and dried under reduced pressure. Yield 47 gr (89%). Melting point 31°C.

Example 6. 33 gr of the same ethyl ester of example 1 were reacted with 29 gr of 1-eicosanol. After the same procedure and the same work up of example 1, 42 gr of wax ester were obtained (75%). Melting point 43°C.

Example 7. The same preparation described in Example 2 was repeated. Crystallization from acetone was omitted, but the raw product obtained after separation of the melted wax from hot water was washed again by the same procedure. A product was obtained, having the same melting point and the same purity as the one described in Example 2. The yield was raised to 96%.

All samples (Examples 1-7) were subjected to hydrolysis according to the conditions described for the analysis of natural wax esters (Linskens, H.J. and Jackson, I.J., Essential Oils and Waxes, Springer Verlag, Berlin (1991)), followed by the proper work up and analysis of the composition of the free fatty acid moiety. Analyses showed the same EPA and DHA content in the wax esters as in the esters utilized as a starting

material.

Example 8. Digestibility test. The effect of pancreas lipase on wax esters has been verified according to the method by Neumann (U.Neumann, P.Kaspar, and J.Ziegenborn, "Methods in Enzymatic Analysis", Bergmayer HV, 1984, vol.4, pp.34-36). 800 mg of wax esters enriched in  $\omega$ -3 polyunsaturated fatty acids, and, in parallel for a comparison, 800 mg of jojoba oil were incubated in a Tris buffer 0.125 M , pH 9.2, containing human pancreas lipase, colipase, and deoxycholic acid for different times at 37°C. After extraction of lipids, portions of organic phases containing lipids were dried and laid down on a silica gel TLC plate with concentration band. Plates were eluted with n-hexane-ethyl ether-acetic acid 80:20:1. Spot were visualized by exposure both to iodine and to sprayed sulphuric acid.



CLAIMS

1. A procedure to prepare wax esters enriched in  $\omega$ -3 unsaturated fatty acids which includes:

- 5 a) the preparation of a mixture of esters of fatty acids, enriched in esters of polyunsaturated fatty acids, whose alcoholic moiety is methyl alcohol, ethyl alcohol or generally a low boiling alcohol;
- 10 b) the transesterification reaction between the enriched mixture described at point a) with one or more alcohols contained in natural wax esters, performed in the presence of a catalyst and by elimination of the low boiling alcohol thus formed by distillation, both at reduced or normal
- 15 pressure;  
or, as an alternative, the direct esterification reaction between acids obtained by hydrolysis of the mixture of enriched esters described at point a) with alcohols of natural wax esters,
- 20 or the reaction between alcohols of natural wax esters and reactive intermediates of the acids, such as anhydrides, chlorides, isopropenyl esters, or the interesterification reaction of methyl and ethyl esters of the fatty acids with acetic or
- 25 propionic esters of long chain alcohols;
- c) the separation of the waxy product and its subsequent purification by recrystallization or by repeated washing with water.
2. A procedure according to claim 1, where the
- 30 starting material is fish oil enriched in esters of polyunsaturated fatty acids EPA and DHA.

3. A procedure, according to claims 1-2, where alcohols of the wax esters of point b) of claim 1 are chosen in the group including behenyl alcohol, stearyl alcohol, tetradecan-1-ol, cetyl alcohol, eicosan-1-ol, oleyl alcohol.
4. Wax esters enriched in  $\omega$ -3 unsaturated fatty acids which can be obtained by the procedure of claims 1-3.
5. Wax esters according to claim 4, enriched in esters of fatty acids EPA and DHA.
6. Wax esters according to claim 5, enriched in behenyl, stearyl, tetradec-1-yl, cetyl, eicos-1-yl, oleyl esters of acids EPA and DHA.
7. Use of wax esters of claims 4-6 for the preparation of drugs for therapy of diseases of the cardiovascular system, of thrombosis, of platelet hyperaggregation, of hyperlipidemia and hypercholesterolemia, of diseases of the immune system, of inflammatory states, and of tumors.
8. Use of wax esters of claims 4-6 for the preparation of dietetic-alimentary integrators.
9. Pharmaceutical preparations containing wax esters of claims 4-6.
10. Dietetic-alimentary integrators containing wax esters of claims 4-6.
11. Dietetic-alimentary integrators according to claim 10 in the form of microspheres or absorbed onto a solid matrix used as food.

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 98/03466

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> IPC 6 C11C3/10 A61K31/23 A23L1/30		
According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) IPC 6 C11C A61K A23L		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	TAKAGI T ET AL: "Gas chromatographic resolution of polyunsaturated wax esters based on their degree of unsaturation on Silar 10C." JOURNAL OF CHROMATOGRAPHIC SCIENCE, vol. 15, no. 3/4, 1977, pages 121-124, XP002083464 Dep. of Chem., Fac. of Fisheries, Hokkaido Univ., Hakodate, Japan see page 121, column 1; table 1 ---	1-6
X	WO 92 22631 A (BEKU ENVIRONMENTAL PRODUCTS LT) 23 December 1992 see example 1 ---	4-6
A	--- see example 1	1-3
X	US 5 463 143 A (SINGLETON DAVID M ET AL) 31 October 1995 see column 1, line 48-61; claim 3 ---	4
-/-		
<div style="display: flex; justify-content: space-between;"> <span><input checked="" type="checkbox"/> Further documents are listed in the continuation of box C.</span> <span><input checked="" type="checkbox"/> Patent family members are listed in annex.</span> </div>		
<div style="display: flex;"> <div style="flex: 1;"> <p>* Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="flex: 1;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&amp;" document member of the same patent family</p> </div> </div>		
Date of the actual completion of the international search  <div style="text-align: center;">6 November 1998</div>		Date of mailing of the international search report  <div style="text-align: center;">27/11/1998</div>
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Authorized officer  <div style="text-align: center;">De Jong, E</div>

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 98/03466

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>DATABASE WPI  Section Ch, Week 9551  Derwent Publications Ltd., London, GB;  Class B05, AN 95-397103  XP002083466  &amp; JP 07 267898 A (NISSHIN FLOUR MILLING  CO), 17 October 1995  see abstract</p> <p>----</p>	1-11
A	<p>WO 90 04013 A (NOVONORDISK AS ;NESTEC LTD  (CH)) 19 April 1990  see page 1-3; claim 1</p> <p>----</p>	1-11
A	<p>GARCIA T ET AL: "Enzymatic synthesis of  an analogue of jojoba oil: optimization by  statistical analysis."  ENZYME AND MICROBIAL TECHNOLOGY,  vol. 15, no. 7, 1993, pages 607-611,  XP002083465  Correspondence (Reprint) address, J.  Aracil, Dep. of Chem. Eng., Fac. of Chem.,  Complutense Univ., 28040 Madrid, Spain  see page 607-608</p> <p>-----</p>	1

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 98/03466

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9222631 A	23-12-1992	AU 666849 B NZ 243075 A	29-02-1996 26-07-1995
US 5463143 A	31-10-1995	AU 3982495 A BR 9509625 A CA 2203388 A WO 9614280 A EP 0804396 A JP 10508531 T	31-05-1996 06-01-1998 17-05-1996 17-05-1996 05-11-1997 25-08-1998
WO 9004013 A	19-04-1990	AU 629866 B AU 4420489 A AU 640353 B AU 4420589 A AU 4421089 A AU 4421189 A AU 631816 B AU 4421989 A AU 630120 B AU 4422089 A AU 639675 B AU 4422289 A AU 636582 B AU 4422489 A CA 2000391 A CA 2000392 A CA 2000393 A CA 2000394 A CA 2000395 A CA 2000396 A CA 2000397 A CA 2000398 A DE 68909053 D DE 68909053 T DK 63091 A DK 63191 A DK 63291 A DK 63391 A DK 63491 A DK 63591 A	15-10-1992 01-05-1990 26-08-1993 01-05-1990 01-05-1990 01-05-1990 10-12-1992 01-05-1990 22-10-1992 01-05-1990 05-08-1993 01-05-1990 06-05-1993 01-05-1990 10-04-1990 10-04-1990 10-04-1990 10-04-1990 10-04-1990 10-04-1990 10-04-1990 10-04-1990 10-04-1990 10-04-1990 14-10-1993 05-01-1994 08-05-1991 08-05-1991 08-05-1991 08-05-1991 08-05-1991 08-05-1991

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 98/03466

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9004013 A		DK 63691 A	08-05-1991
		DK 63791 A	08-05-1991
		WO 9004008 A	19-04-1990
		WO 9004009 A	19-04-1990
		WO 9004010 A	19-04-1990
		WO 9003786 A	19-04-1990
		WO 9003787 A	19-04-1990
		WO 9004011 A	19-04-1990
		WO 9004012 A	19-04-1990
		EP 0437518 A	24-07-1991
		EP 0437519 A	24-07-1991
		EP 0437520 A	24-07-1991
		EP 0437521 A	24-07-1991
		EP 0437522 A	24-07-1991
		EP 0438483 A	31-07-1991
		EP 0437523 A	24-07-1991
		EP 0437524 A	24-07-1991
		JP 4500971 T	20-02-1992
		JP 4500972 T	20-02-1992